|
“Melatonin Treatment for Insomnia in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder (January),” Bendz LM, Scates AC, Ann Pharmacother, 2009 Dec 22; [Epub ahead of print]. (Address: Drug Information Specialty Resident, Department of Pharmacy, Duke University Hospital, Durham, NC, USA).
|
|
In this article, the authors reviewed the efficacy and safety of melatonin in the treatment of insomnia in pediatric patients with attention-deficit/hyperactivity disorder (ADHD). Literature was accessed through MEDLINE, EMBASE and Scopus. Results from 5 randomized trials, 1 safety study, 1 long-term follow-up study, 1 retrospective analysis, 2 meta-analyses, 9 review articles and 1 letter were summarized and found to show that melatonin is a well-tolerated and efficacious treatment option for children with chronic sleep-onset insomnia and ADHD. Studies included children 6-14 years old and melatonin doses ranged from 3 to 6 mg administered within a few hours of a scheduled bedtime.
|